NCT01578928View on ClinicalTrials.gov

A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Renal Impairment
Interventions
DRUG

SOM230

Trial Locations (2)

9300

Novartis Investigative Site, Bloemfontein

14050

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT01578928 - A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers | Biotech Hunter | Biotech Hunter